Supplements
CNS Summit 2018 Abstracts of Poster Presentations
A message from the editor: Dear Colleagues: Welcome to the annual CNS Summit Abstracts of Poster Presentations supplement to Innovations in Clinical Neuroscience. We are pleased to provide you with this reference guide to some of the innovative research that is being presented during CNS Summit 2018. The supplement is also available online by visiting […]
Hot Topics in Multiple Sclerosis
Click the cover below to access the digital editions of Hot Topics in Multiple Sclerosis! June 2018 March 2018 December 2017 November 2017
Hot Topics in Pain Management
Click the cover below to access the digital editions of Hot Topics in Pain Management! October 2017 September 2017 August 2017 July 2017
CNS Summit 2016 Abstracts of Poster Presentations
Innov Clin Neurosci. 2017;14(1–2)3–23 A MESSAGE FROM THE EDITOR Dear Colleagues: Welcome to the annual CNS Summit Abstracts of Poster Presentations supplement to Innovations in Clinical Neuroscience. We are pleased to provide you with this reference guide to some of the innovative research that was presented during CNS Summit 2016, which was held October 27 […]
Supplement to November–December 2015 Issue: Abstracts of Poster Presentations: CNS Summit 2015
October 7–11, 2015 Boca Raton, Florida Innov Clin Neurosci. 2015;12(11–12 Suppl C):3–17 CNS Drug Compounds Synthesis of carnitine analogues for inhibition of carnitine palmitoyltransferase Presenters: Bornstein J, Garneau-Tsodikova S Affiliations: University of Michigan Life Sciences Institute Background: Type 2 diabetes (T2DM) carries a markedly elevated risk of cerebrovascular disease. Carnitine plays a key role transporting […]
Supplement to May–June 2015 Issue: CNS Summit 2014 Abstracts of Poster Presentations
Innov Clin Neurosci. 2015;12(5–6 Suppl B):3–19 CNS Drug Compounds/Therapies/Devices Long-acting injectable antipsychotics (LAIs) in outpatient treatment of DMS-IV-R schizophrenia Presenters: Bellnier T, Patil K, Ortega T, Seeger G Affiliations: SUNY University at Buffalo, GPI Clinical Research Background: The treatment of schizophrenia with LAIs is a significant focus of drug development. The cost of re-hospitalization due […]
Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium
by Jared W. Young, PhD; William Z. Potter, MD, PhD; Steve Riley, PharmD, PhD; Geert J. Groeneveld, MD, PhD; Bruce J. Kinon, MD; Mike F. Egan, MD; and Douglas E. Feltner, MD Dr. Young is with the Department of Psychiatry, University of California San Diego, La Jolla, California, and Research Service, VA San Diego Healthcare […]
Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments
by Steven T. Szabo, MD, PhD; Bruce J. Kinon, MD; Stephen K. Brannan, MD; Andrew K. Krystal, MD, MSc; Joop M A van Gerven, MD, PhD; Atul Mahableshwarkar, MD; and Gary S. Sachs, MD Dr. Szabo is with Duke University Medical Center, Durham, North Carolina, and Veterans Administration Medical Center, Durham, North Carolina; Dr. Kinon […]
Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia
by Harald Murck, MD, PhD; Thomas Laughren, MD; Femke Lamers, PhD; Rosalind Picard, ScD; Sebastian Walther, MD; Donald Goff, MD; and Stephen Sainati, MD, PhD Dr. Murck is with Acorda Therapeutics in Ardsley, New York, and Phillips-University Marburg, Marburg, Germany (Dr. Murck was with Covance Inc., Princeton, New Jersey, during the preparation of this manuscript); […]
